Egis Pharmaceuticals PLC Tech Stack

Central European generic pharma manufacturer with biosimilar capability

Pharmaceutical Manufacturing Budapest 1,001–5,000 employees Founded 1913 Privately Held

Egis manufactures generic drugs and biosimilars across Central Eastern Europe, with 2022/2023 revenue of EUR 631.7 million and R&D spending above EUR 45 million annually. The company is mid-stage in a major SAP modernization (S/4HANA adoption, replacing R/3) while scaling manufacturing operations — hiring accelerating across production, engineering, and quality roles. Active projects span process validation, new product launches, and regulatory compliance (MDR transition), indicating a company balancing growth with tightening pharmaceutical standards.

Tech Stack 41 technologies

Core StackAutoCAD SAP SAP S/4HANA Windows Server Active Directory SQL Server VMware Oracle ABAP SAP MM ArchiCAD Microsoft Office Excel Word HPLC GCP SAP QM SAP R/3 DHCP DNS Group Policy IIS SharePoint Microsoft 365 Azure Zabbix MES PowerPoint SAP GRC Outlook+11 more

AdoptingSAP S/4HANA

ReplacingSAP R/3

What Egis Pharmaceuticals PLC Is Building

◆Challenges

Managing capa processes
Transition to mdr
S/4hana transformation
Ensuring gmp compliance
Inventory management of spare parts
Acquiring new customers
Improving warehouse quality assurance processes
Coordinating nonconformity investigations
Ensuring commercial viability of collaboration projects
Efficiency and quality improvement

▲Active Projects

Pqr process development
Vmp system development
New product introduction
Strategic commercial plan development
Building renovation
Product development analytical documentation
S/4hana transformation
New machine commissioning
New product development and launch
Software validation

Hiring Activity

Accelerating160 roles · 70 in 30d

Department

Manufacturing

Engineering

Ops

Sales

Research

Logistics

Quality

Finance

Seniority

Mid

Intern

Junior

Senior

Manager

Director

Lead

Notable leadership hires: Clinical trial lead, Analytical development head

Company intelligence

Find more companies like Egis Pharmaceuticals PLC by tech stack, pain points and active projects

Get started free

About Egis Pharmaceuticals PLC

Egis is a leading generic pharmaceutical manufacturer headquartered in Budapest, owned by Servier, a global pharma group governed as a Foundation. The company operates across the full pharma value chain: active ingredient synthesis, tablet and injection manufacturing, and galenic formulations. Products reach 100 countries through subsidiaries, representative offices, and partners in 18 countries under the Egis brand. Therapeutic focus spans cardiovascular, central nervous system, diabetology, and skin/wound care. Since 2013, Egis has launched four biosimilar monoclonal antibodies, including the first mAb approved in the EU. Over the past 20 years, the company invested more than EUR 770 million in Hungarian facilities, establishing modern manufacturing plants and R&D centers.

HeadquartersBudapest

Company Size1,001–5,000 employees

Founded1913

Hiring MarketsHungary, Latvia

Frequently Asked Questions

What countries does Egis Pharmaceuticals operate in?

Egis sells under its brand in 18 countries directly and distributes to 100 countries total via subsidiaries, representative offices, and partners. Current hiring is active in Hungary and Latvia.

What is Egis Pharmaceuticals' tech stack?

Core systems: SAP (S/4HANA, R/3, QM, MM, GRC, ABAP), SQL Server, Oracle, Azure, GCP. Manufacturing: HPLC, MES, AutoCAD, ArchiCAD. IT infrastructure: Active Directory, Windows Server, SharePoint, VMware. Monitoring: Zabbix.